Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | UBE2N | P61088 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24684889 | 0.83 | NPC1 (0.32) | MAPTNPC1RAB9AMAPK1SMN1; SMN2 | |
| SCHEMBL1106089 | 0.80 | CA2 (0.33) | MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL18235325 | 0.74 | — | — | |
| SCHEMBL19388420 | 0.72 | MAPT (0.32) | MAPTNPC1RAB9AMAPK1SMN1; SMN2 | |
| SCHEMBL12596204 | 0.71 | NPC1 (0.33) | MAPTNPC1RAB9AMAPK1SMN1; SMN2 | |
| SCHEMBL12948196 | 0.70 | GABRA1 (0.34) | — | |
| SCHEMBL22023990 | 0.67 | KCNA3 (0.37) | NPC1RAB9AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL19203370 | 0.66 | MEN1 (0.35) | MAPTNPC1RAB9AMAPK1SMN1; SMN2 | |
| SCHEMBL799943 | 0.66 | HPGD (0.32) | MAPT | |
| SCHEMBL24324388 | 0.65 | CA2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177462-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177462-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | MAPT 3008/4885NPC1 1465/4885RAB9A 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.